Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients who have
refractory or relapsed multiple myeloma or Castleman's disease.